Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Lung Neoplasms/*drug therapy/pathology"'
Scientists are increasingly focusing attention on natural products of plant origin for use as agents in cancer protection and treatment. Cyclamen L. tuber extracts contain saponin glycosides that have been shown to have anti-cancer and other biologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3566::ab911a2128381ff617cf5d1e20fa36cd
Autor:
Elisabeth, Quoix, Virginie, Westeel, Lionel, Moreau, Eric, Pichon, Armelle, Lavolé, Jérome, Dauba, Didier, Debieuvre, Pierre Jean, Souquet, Laurence, Bigay-Game, Eric, Dansin, Michel, Poudenx, Olivier, Molinier, Fabien, Vaylet, Denis, Moro-Sibilot, Denis, Herman, Helene, Sennelart, Jean, Tredaniel, Bertrand, Mennecier, Franck, Morin, Laurence, Baudrin, Bernard, Milleron, Gérard, Zalcman, N, Le Flour
Publikováno v:
European Respiratory Journal
European Respiratory Journal, European Respiratory Society, 2014, 43, pp.240--9. ⟨10.1183/09031936.00048213⟩
European Respiratory Journal, 2014, 43, pp.240--9. ⟨10.1183/09031936.00048213⟩
European Respiratory Journal, European Respiratory Society, 2014, 43, pp.240--9. ⟨10.1183/09031936.00048213⟩
European Respiratory Journal, 2014, 43, pp.240--9. ⟨10.1183/09031936.00048213⟩
There is no dedicated study on second-line treatment for elderly patients with advanced nonsmall cell lung cancer (NSCLC). We report the results on second-line erlotinib therapy from our previously published phase III study comparing single-agent the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b669b7c6d336cdca82ec2ec8bc816bea
https://doi.org/10.1183/09031936.00048213
https://doi.org/10.1183/09031936.00048213
Autor:
Epaminontas Samantas, George Fountzilas, H. P. Kalofonos, Meletios A. Dimopoulos, E. Briasoulis, D.V. Skarlos, T. Economopoulos, Kostas N. Syrigos, D.G. Pectasides, P. Kosmidis
Publikováno v:
Lung Cancer. 58:355-361
Summary Objective The purpose of this study was to evaluate the efficacy and toxicity of cisplatin, etoposide and irinotecan as first-line treatment in patients with extensive small-cell lung cancer (E-SCLC). Patients and methods Chemo-naive adult pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f157cbccecb0a750924122a4a25188
https://doi.org/10.1016/j.lungcan.2007.06.027
https://doi.org/10.1016/j.lungcan.2007.06.027
Publikováno v:
Revue médicale suisse, Vol. 11, No 475 (2015) pp. 1103-1107
In incurable diseases, maintenance therapy aims to prolong the response achieved through induction. The goal is to delay disease progression, thus prolonging survival. Two maintenance modalities are used. The first, called continuation maintenance, c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1400::4fb4627b891e2b59cb732129c001142c
https://archive-ouverte.unige.ch/unige:90182
https://archive-ouverte.unige.ch/unige:90182
Autor:
Briassoulis, E. Ch, Samantas, E., Kalofonos, H. P., Skarlos, Dimosthenis V., Makatsoris, T., Christodoulou, C., Fountzilas, George, Bamias, A. T., Dimopoulos, M. A., Kosmidis, Paraskevas A., Pavlidis, Nicholas
Publikováno v:
Cancer chemotherapy and pharmacology
AIM: The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. METHODS: Successive coh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff2618c16a6a2974616324845805afa
https://doi.org/10.1007/s00280-004-0994-8
https://doi.org/10.1007/s00280-004-0994-8
Autor:
P. Kosmidis, C. Bakogiannis, Sofia Lambaki, J. Boukovinas, Anastasia G Eleftheraki, Kostas N. Syrigos, George Fountzilas, Meletios A. Dimopoulos, D.G. Pectasides, N. Katirtzoglou, D.V. Skarlos, Dimitris Bafaloukos, Georgios Pentheroudakis, H. P. Kalofonos, Epaminontas Samantas
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 22(4)
BACKGROUND: Paclitaxel (Taxol) and vinorelbine have shown synergism of cytotoxic effects in vitro and clinical activity in phase I and II studies. This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1666c49f61b226f0892b48620b169b18
https://pubmed.ncbi.nlm.nih.gov/20880999
https://pubmed.ncbi.nlm.nih.gov/20880999
Autor:
Pavlidis, Nicholas, Hanauske, A. R., Gamucci, T., Smyth, J. F., Lehnert, M., Velde, A. Te, Lan, J., Verweij, J.
Publikováno v:
Annals of Oncology
In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bioreductive alkylating indoloquinone. The drug was given at two different dose sch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73c98c1ad912115bcfe2ddf13840f09b
https://doi.org/10.1093/oxfordjournals.annonc.a010645
https://doi.org/10.1093/oxfordjournals.annonc.a010645
Autor:
Lakka, S. S., Rajagopal, R., Rajan, M. K., Mohan, P. M., Adachi, Y., Dinh, D. H., Olivero, W. C., Gujrati, M., Ali-Osman, F., Roth, J. A., Yung, W. K., Kyritsis, A. P., Rao, J. S.
The urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play an important role in the proteolytic cascade involved in the metastasis of lung and other cancers. We report that the reduction in uPAR levels produced by an antisense strate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::ebc40e2150b303af8938ab01a2e8d122
http://olympias.lib.uoi.gr/jspui/handle/123456789/24058
http://olympias.lib.uoi.gr/jspui/handle/123456789/24058
Autor:
Kosmidis, P., Mylonakis, N., Skarlos, D., Samantas, E., Dimopoulos, M., Papadimitriou, C., Kalophonos, C., Pavlidis, N., Nikolaidis, C., Papaconstantinou, C., Fountzilas, G.
PURPOSE: The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present prospective study was to eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::dc5cfd2358dc6bd51bd57012c5b12426
http://olympias.lib.uoi.gr/jspui/handle/123456789/19500
http://olympias.lib.uoi.gr/jspui/handle/123456789/19500
Autor:
Gamucci, T., Paridaens, R., Heinrich, B., Schellens, J. H. M., Pavlidis, Nicholas, Verweij, J., Sessa, Cristiana, Kaye, Stanley B., Roelvink, M., Wanders, J., Hanauske, A. R.
Publikováno v:
Annals of Oncology
Annals of Oncology, 11, 793-797. Elsevier Ltd.
Annals of Oncology, 11, 793-797. Elsevier Ltd.
Background: GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. Patients and methods: Between April 1995 and November 1996, 67 eligible patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8c8eaad71738097542bdb1a030b744b
http://olympias.lib.uoi.gr/jspui/handle/123456789/24116
http://olympias.lib.uoi.gr/jspui/handle/123456789/24116